Nothing said here yet.
to join the conversation.
| Mercier JohannaChief Comm & Corp Aff Officer | Sell | 3,000 | $468.7K | Thu, Oct 15 |
| Dickinson Andrew DChief Financial Officer | Sell | 3,000 | $468.7K | Thu, Oct 15 |
| O'Day Daniel PatrickChairman & CEO | Sell | 12,000 | $1.8M | Thu, Oct 1 |
| O'Day Daniel PatrickChairman & CEO | Sell | 3,000 | $445.9K | Thu, Oct 1 |
| Dickinson Andrew DChief Financial Officer | Sell | 3,000 | $435.9K | Tue, Sep 15 |
| Mercier JohannaChief Comm & Corp Aff Officer | Sell | 1,600 | $229.9K | Tue, Sep 15 |
| Mercier JohannaChief Comm & Corp Aff Officer | Sell | 800 | $115.6K | Tue, Sep 15 |
| Mercier JohannaChief Comm & Corp Aff Officer | Sell | 600 | $87.2K | Tue, Sep 15 |
| O'Day Daniel PatrickChairman & CEO | Sell | 7,992 | $1.2M | Tue, Sep 1 |
| O'Day Daniel PatrickChairman & CEO | Sell | 5,408 | $807.9K | Tue, Sep 1 |
| O'Day Daniel PatrickChairman & CEO | Sell | 1,600 | $236.0K | Tue, Sep 1 |
| WELTERS ANTHONYDirector | Sell | 6,880 | $1.0M | Wed, Aug 26 |
| Thomas H Tubervilleoptions | Buy | $24.0K | Fri, May 10 | Wed, Aug 5 |
| Thomas H Tuberville | Sell | $8.0K | Wed, May 8 | Wed, Aug 5 |
| Alan Armstrong | Buy | $8.0K | Fri, Mar 27 | Tue, Jul 21 |
| Jared Moskowitz | Buy | $16.0K | Wed, May 6 | Sun, May 31 |
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 6.8% year on year to $8.3 billion.
Gilead Sciences (GILD) continues to benefit from strong demand for its HIV medicines, helping suppor
Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.
Gilead Sciences (NasdaqGS:GILD) secured a pan Canadian public reimbursement agreement for LYVDELZI (seladelpar) for primary biliary cholangitis.
Gilead raises its 2026 sales outlook on strong HIV growth, even as Biktarvy faces a $1.5 billion pricing headwind in 2028. What's driving its momentum?
Gilead Sciences (NASDAQ:GILD) shares surged 4. 5% to $172.
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.